Reference Detail

Ref Type
PMID
Authors Venkatesh Pilla Reddy, Aaron Smith, Michael Grondine, Rana Anjum, Rhys D. Jones
Title Exploring the pharmacokinetic-pharmacodynamic relationships of AZD3229, a novel and selective inhibitor of cKIT, in a range of mouse xenograft models of gastrointestinal stromal tumors.
Journal Proceedings of the American Association for Cancer Research
Vol
Issue
Date
URL https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf
Abstract Text Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
AZD3229 AZD3229 4 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
AZD3229 KIT Inhibitor 50 AZD3229 is a selective Kit inhibitor that may have anti-tumor activity against KIT-driven tumors (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KIT D816H Advanced Solid Tumor predicted - sensitive AZD3229 Preclinical - Cell line xenograft Actionable In a preclinical study, AZD3229 inhibited Kit signaling, resulted in tumor regression in cell line xenograft models of transformed cells expressing KIT D816H (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328). detail...
KIT exon 11 del gastrointestinal stromal tumor predicted - sensitive AZD3229 Preclinical - Cell line xenograft Actionable In a preclinical study, AZD3229 inhibited Kit signaling, resulted in tumor regression in cell line xenograft models of gastrointestinal stromal tumor harboring KIT exon 11 deletion mutation (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328). detail...
KIT Y823D gastrointestinal stromal tumor predicted - sensitive AZD3229 Preclinical - Pdx Actionable In a preclinical study, AZD3229 inhibited Kit signaling, resulted in tumor regression in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor harboring KIT Y823D (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328). detail...
KIT V654A gastrointestinal stromal tumor predicted - sensitive AZD3229 Preclinical - Pdx Actionable In a preclinical study, AZD3229 inhibited Kit signaling, resulted in tumor regression in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor harboring KIT V654A (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328). detail...